CD150- Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and is Depleted by Genetic Loss of SIRT1

Stem Cells

Volumn 33, Issue 12, 2015, Pages 3437-3451

  Wang, Zhiqiang ^a   Chen, Ching Cheng ^a   Chen, Wenyong ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Hematopoietic stem cells; Leukemia stem cells; Side population; SIRT1

Indexed keywords

BCR ABL PROTEIN; CD150 ANTIGEN; CYCLIN DEPENDENT KINASE 6; PROTEIN P53; RETROVIRUS VECTOR; SIRTUIN 1; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; SIRT1 PROTEIN, MOUSE; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER STEM CELL; CELL COUNT; CELL LINEAGE; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DEACETYLATION; ENZYME INHIBITION; GENE DELETION; GENE LOSS; HEMATOPOIETIC STEM CELL; LEUKEMIA STEM CELL; MOUSE; NONHUMAN; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BAGG ALBINO MOUSE; EXPERIMENTAL LEUKEMIA; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD; GENE DELETION; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; RECEPTORS, CELL SURFACE; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE FAMILY MEMBER 1; SIRTUIN 1;

EID: 84983134854     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2218     Document Type: Article

References (61)

1. Valent P, Bonnet D, De Maria R, et al., Cancer stem cell definitions and terminology: The devil is in the details. Nat Rev Cancer 2012; 12: 767-775.
2. Ren R,. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
3. Jamieson CH, Ailles LE, Dylla SJ, et al., Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
4. Perrotti D, Jamieson C, Goldman J, et al., Chronic myeloid leukemia: Mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254-2264.
5. Holtz MS, Slovak ML, Zhang F, et al., Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002; 99: 3792-3800.
6. Graham SM, Jorgensen HG, Allan E, et al., Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
7. Bhatia R, Holtz M, Niu N, et al., Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
8. Daley GQ, Van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
9. Pear WS, Miller JP, Xu L, et al., Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
10. Ito K, Bernardi R, Morotti A, et al., PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078.
11. Naka K, Hoshii T, Muraguchi T, et al., TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
12. Morrison SJ, Weissman IL,. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994; 1: 661-673.
13. Spangrude GJ, Brooks DM,. Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A/E by bone marrow cells. Blood 1993; 82: 3327-3332.
14. Goodell MA, Brose K, Paradis G, et al., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
15. Kiel MJ, Yilmaz OH, Iwashita T, et al., SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121.
16. Roth M, Chen WY,. Sorting out functions of sirtuins in cancer. Oncogene 2014; 33: 1609-1620.
17. Houtkooper RH, Pirinen E, Auwerx J,. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13: 225-238.
18. Yuan H, Wang Z, Li L, et al., Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012; 119: 1904-1914.
19. Li L, Wang L, Wang Z, et al., Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012; 21: 266-281.
20. Hu Y, Smyth GK,. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
21. Challen GA, Boles N, Lin KK, et al., Mouse hematopoietic stem cell identification and analysis. Cytometry A 2009; 75: 14-24.
22. Weksberg DC, Chambers SM, Boles NC, et al., CD150- side population cells represent a functionally distinct population of long-term hematopoietic stem cells. Blood 2008; 111: 2444-2451.
23. Goodell MA, Rosenzweig M, Kim H, et al., Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3: 1337-1345.
24. Chen WY, Bailey EC, McCune SL, et al., Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997; 94: 5798-5803.
25. Challen GA, Boles NC, Chambers SM, et al., Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell 2010; 6: 265-278.
26. Matsumoto A, Takeishi S, Kanie T, et al., p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell 2011; 9: 262-271.
27. Zou P, Yoshihara H, Hosokawa K, et al., p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 2011; 9: 247-261.
28. Laurenti E, Frelin C, Xie S, et al., CDK6 levels regulate quiescence exit in human hematopoietic stem cells. Cell Stem Cell 2015; 16: 302-313.
29. Scheicher R, Hoelbl-Kovacic A, Bellutti F, et al., CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood 2015; 125: 90-101.
30. Kataoka K, Sato T, Yoshimi A, et al., Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med 2011; 208: 2403-2416.
31. Goyama S, Yamamoto G, Shimabe M, et al., Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3: 207-220.
32. Stein SJ, Baldwin AS,. Deletion of the NF-kappaB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood 2013; 121: 5015-5024.
33. Reuther JY, Reuther GW, Cortez D, et al., A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998; 12: 968-981.
34. Kirchner D, Duyster J, Ottmann O, et al., Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol 2003; 31: 504-511.
35. Hamdane M, David-Cordonnier MH, D'Halluin JC,. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 1997; 15: 2267-2275.
36. TeKippe M, Harrison DE, Chen J,. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 2003; 31: 521-527.
37. Akala OO, Park IK, Qian D, et al., Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature 2008; 453: 228-232.
38. Hu Y, Swerdlow S, Duffy TM, et al., Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870-16875.
39. Koschmieder S, Gottgens B, Zhang P, et al., Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324-334.
40. Zhang B, Ho YW, Huang Q, et al., Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012; 21: 577-592.
41. Dash AB, Williams IR, Kutok JL, et al., A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 2002; 99: 7622-7627.
42. Minami Y, Stuart SA, Ikawa T, et al., BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105: 17967-17972.
43. Neering SJ, Bushnell T, Sozer S, et al., Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007; 110: 2578-2585.
44. Schemionek M, Elling C, Steidl U, et al., BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010; 115: 3185-3195.
45. Zhang S, Ramsay ES, Mock BA,. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci USA 1998; 95: 2429-2434.
46. Zhang S, Qian X, Redman C, et al., p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene 2003; 22: 2285-2295.
47. Serrano M,. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 2000; 21: 865-869.
48. Schmitt CA, McCurrach ME, de Stanchina E, et al., INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670-2677.
49. Calabretta B, Perrotti D,. The biology of CML blast crisis. Blood 2004; 103: 4010-4022.
50. Williams RT, Roussel MF, Sherr CJ,. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006; 103: 6688-6693.
51. Kusy S, Larsen CJ, Roche J,. p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia. Leuk Lymphoma 2004; 45: 1989-1994.
52. Wang Z, Liu Z, Wu X, et al., ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance. PLoS Genet 2014; 10: e1004414.
53. Wang Z, Yuan H, Roth M, et al., SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene 2013; 32: 589-598.
54. Li L, Osdal T, Ho Y, et al., SIRT1 Activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 2014; 15: 431-446.
55. Sasca D, Hahnel PS, Szybinski J, et al., SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014; 124: 121-133.
56. Singh SK, Williams CA, Klarmann K, et al., Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenance. J Exp Med 2013; 210: 987-1001.
57. Rimmele P, Bigarella CL, Liang R, et al., Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cells. Stem Cell Reports 2014; 3: 44-59.
58. Leko V, Varnum-Finney B, Li H, et al., SIRT1 is dispensable for function of hematopoietic stem cells in adult mice. Blood 2012; 119: 1856-1860.
59. Narala SR, Allsopp RC, Wells TB, et al., SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell 2008; 19: 1210-1219.
60. Roth M, Wang Z, Chen WY,. Sirtuins in hematological aging and malignancy. Crit Rev Oncog 2013; 18: 531-547.
61. Chen WY, Bhatia R,. Roles of SIRT1 in leukemogenesis. Curr Opin Hematol 2013; 20: 308-313.